These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29385573)

  • 1. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.
    Tan YM; Worley RR; Leonard JA; Fisher JW
    Toxicol Sci; 2018 Apr; 162(2):341-348. PubMed ID: 29385573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK model reporting template for chemical risk assessment applications.
    Tan YM; Chan M; Chukwudebe A; Domoradzki J; Fisher J; Hack CE; Hinderliter P; Hirasawa K; Leonard J; Lumen A; Paini A; Qian H; Ruiz P; Wambaugh J; Zhang F; Embry M
    Regul Toxicol Pharmacol; 2020 Aug; 115():104691. PubMed ID: 32502513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A framework for application of quantitative property-property relationships (QPPRs) in physiologically based pharmacokinetic (PBPK) models for high-throughput prediction of internal dose of inhaled organic chemicals.
    Chebekoue SF; Krishnan K
    Chemosphere; 2019 Jan; 215():634-646. PubMed ID: 30347358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency.
    Luzon E; Blake K; Cole S; Nordmark A; Versantvoort C; Berglund EG
    Clin Pharmacol Ther; 2017 Jul; 102(1):98-105. PubMed ID: 27770430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.
    McLanahan ED; El-Masri HA; Sweeney LM; Kopylev LY; Clewell HJ; Wambaugh JF; Schlosser PM
    Toxicol Sci; 2012 Mar; 126(1):5-15. PubMed ID: 22045031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
    Tylutki Z; Mendyk A; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry.
    el-Masri HA; Mumtaz MM; Choudhary G; Cibulas W; De Rosa CT
    Int J Hyg Environ Health; 2002 Mar; 205(1-2):63-9. PubMed ID: 12018017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.
    Khalil F; Läer S
    J Biomed Biotechnol; 2011; 2011():907461. PubMed ID: 21716673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Toxicology Tools and the Emerging Paradigm Shift in Environmental Health Decision-Making.
    Ginsberg GL; Pullen Fedinick K; Solomon GM; Elliott KC; Vandenberg JJ; Barone S; Bucher JR
    Environ Health Perspect; 2019 Dec; 127(12):125002. PubMed ID: 31834829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment.
    Lin Z; Gehring R; Mochel JP; Lavé T; Riviere JE
    J Vet Pharmacol Ther; 2016 Oct; 39(5):421-38. PubMed ID: 27086878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments.
    Cohen Hubal EA; Wetmore BA; Wambaugh JF; El-Masri H; Sobus JR; Bahadori T
    J Expo Sci Environ Epidemiol; 2019 Jan; 29(1):11-20. PubMed ID: 30116055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole body pharmacokinetic models.
    Nestorov I
    Clin Pharmacokinet; 2003; 42(10):883-908. PubMed ID: 12885263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.